Not Yet RecruitingPhase 1ACTRN12605000727640

Angiogenesis II-Safety and feasibility of autologous mesenchymal precursor cells (MPCs) in chronic myocardial ischaemia.

Sponsor

Mesoblast

Enrollment

10 participants

Start Date

Nov 2, 2006

Study Type

Interventional

Conditions

Sex: Both males and females

Canadian Cardiologic Society (CCS) Angina Scale class III or IV. Attempted best medical therapy including long acting nitrates, beta-blockers, and calcium channel blockers. Doses of each medication should be increased until haemodynamic consequences (bradycardia or hypotension) or intolerable drug-related side effects. Clinical signs and symptoms of significant ischaemia with reversible myocardial ischaemia on perfusion imaging. Subject must be able to complete a minimum of 3 minutes but no more than 10 minutes of Modified Bruce protocol.

Unprotected left main coronary artery disease >50%. Unstable angina pectoris (labile ECG changes) or a change in anti - anginal medication within the last three weeks. Myocardial infarction (Q wave or non-Q wave) and cerebrovascular events within the last three months. Left ventricular (LV) thrombus. Severe peripheral vascular disease precluding femoral artery access. Aortic stenosis that prohibited catheter access to the LV. De - compensated heart failure and/ or severe LV dysfunction (ejection fraction <30%). Hypertrophic or restrictive cardiomyopathy.

Interested in this trial?

Get notified about updates and connect with the research team.

Left ventericular electromechanical mapping and adminsitration of MPCs

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

ACTRN12605000727640